| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2004-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd1c66f1b5eca6fe8bd8bfd186293bd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6e40e9a1399844c0faff5b45c258cc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7ca5f7198784c70db1c25463d3c7a33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eed1e8753af43a883b71a015a26b8f67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a9272b49af4033797215a71ec11325d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a48e215e36fff850a579986427d43ad1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5417bf29b031b9e4474909a30455eb2d |
| publicationDate |
2018-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3354261-A1 |
| titleOfInvention |
Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion |
| abstract |
A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant. |
| priorityDate |
2003-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |